Erratum: Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates (British Journal of Pharmacology (2006) 148, (1116-1123) DOI: 10.1038/sj.bjp.0706828);Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates

British Journal of Pharmacology

Volumn 148, Issue 8, 2006, Pages 1116-1123

  Kelley, Sean K ^a   Gelzleichter, Thomas ^a   Xie, Dong ^a   Lee, Wyne P ^a   Darbonne, Walter C ^a   Qureshi, Ferhan ^a   Kissler, Kim ^b   Oflazoglu, Ezogelin ^b   Grewal, Iqbal S ^a,b  

^a GENENTECH INC   (United States)

^b SEATTLE GENETICS INC   (United States)

Author keywords

Animal models; Anti CD40; B cell; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CD20 ANTIGEN; CD40 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD40; SGN 40; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER MODEL; CANCER SURVIVAL; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; LYMPHOMA CELL LINE; MACACA; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SCID MOUSE; SPECIES COMPARISON; TUMOR XENOGRAFT;

EID: 33747104543     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707129     Document Type: Erratum

References (32)

1. AGGARWAL, B.B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol., 3, 745-756.
2. BANCHEREAU, J., BAZAN, F., BLANCHARD, D., BRIERE, F., GALIZZI, J.P., VAN KOOTEN, C., LIU, Y.J., ROUSSET, F. & SAELAND, S. (1994). The CD40 antigen and its ligand. Annu. Rev. Immunol., 12, 881-922.
3. DILLOO, D., BROWN, M., ROSKROW, M., ZHONG, W., HOLLADAY, M., HOLDEN, W. & BRENNER, M. (1997). CD40 ligand induces an antileukemia immune response in vivo. Blood, 90, 1927-1933.
4. ELIOPOULOS, A.G., DAVIES, C., KNOX, P.G., GALLAGHER, N.J., AFFORD, S.C., ADAMS, D.H. & YOUNG, L.S. (2000). CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol. Cell. Biol., 20, 5503-5515.
5. ELIOPOULOS, A.G., DAWSON, C.W., MOSIALOS, G., FLOETTMANN, J.E., ROWE, M., ARMITAGE, R.J., DAWSON, J., ZAPATA, J.M., KERR, D.J., WAKELAM, M.J., REED, J.C., KIEFF, E. & YOUNG, L.S. (1996). CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene, 13, 2243-2254.
6. ELIOPOULOS, A.G. & YOUNG, L.S. (2004). The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol., 4, 360-367.
7. FRANCISCO, J.A., DONALDSON, K.L., CHACE, D., SIEGALL, C.B. & WAHL, A.F. (2000). Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Res., 60, 3225-3231.
8. FUNAKOSHI, S., LONGO, D.L., BECKWITH, M., CONLEY, D.K., TSARFATY, G., TSARFATY, I., ARMITAGE, R.J., FANSLOW, W.C., SPRIGGS, M.K. & MURPHY, W.J. (1994). Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood, 83, 2787-2794.
9. GHAMANDE, S., HYLANDER, B.L., OFLAZOGLU, E., LELE, S., FANSLOW, W. & REPASKY, E.A. (2001). Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res., 61, 7556-7562.
10. GIBALDI, M. & PERRIER, D. (1982). Pharmacokinetics, 2nd edn., revised and expanded. New York: Markel Dekker Inc.
11. GREWAL, I.S. & FLAVELL, R.A. (1998). CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol., 16, 111-135.
12. HAYASHI, T., TREON, S.P., HIDESHIMA, T., TAI, Y.T., AKIYAMA, M., RICHARDSON, P., CHAUHAN, D., GREWAL, I.S. & ANDERSON, K.C. (2003). Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br. J. Haematol., 121, 592-596.
13. HESS, S. & ENGELMANN, H. (1996). A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med., 183, 159-167.
14. HIRANO, A., LONGO, D.L., TAUB, D.D., FERRIS, D.K., YOUNG, L.S., ELIOPOULOS, A.G., AGATHANGGELOU, A., CULLEN, N., MACARTNEY, J., FANSLOW, W.C. & MURPHY, W.J. (1999). Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood, 93, 2999-3007.
15. HOLLMANN, A.C., GONG, Q. & OWENS, T. (2002). CD40-mediated apoptosis in murine B-lymphoma lines containing mutated p53. Exp. Cell Res., 280, 201-211.
16. INGS, R.M.J. (1990). Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica, 20, 1201-1231.
17. INSTITUTE OF LABORATORY ANIMAL RESEARCH, COMMISSION ON LIFE SCIENCES, NATIONAL RESEARCH COUNCIL. (1996). Guide for the care and use of laboratory animals. p 140, Washington, DC, U.S.A.: National Academy Press.
18. LAW, C.L., GORDON, K.A., COLLIER, J., KLUSSMAN, K., MCEARCHERN, J.A., CERVENY, C.G., MIXAN, B.J., LEE, W.P., LIN, Z., VALDEZ, P., WAHL, A.F. & GREWAL, I.S. (2005). Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res., 65, 8331-8338.
19. MATHUR, R.K., AWASTHI, A., WADHONE, P., RAMANAMURTHY, B. & SAHA, B. (2004). Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat. Med., 10, 540-544.
20. OTTAIANO, A., PISANO, C., DE CHIARA, A., ASCIERTO, P.A., BOTTI, G., BARLETTA, E., APICE, G., GRIDELLI, C. & IAFFAIOLI, V.R. (2002). CD40 activation as potential tool in malignant neoplasms. Tumori, 88, 361-366.
21. PELLAT-DECEUNYNCK, C., BATAILLE, R., ROBILLARD, N., HAROUSSEAU, J.L., RAPP, M.J., JUGE-MORINEAU, N., WIJDENES, J. & AMIOT, M. (1994). Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood, 84, 2597-2603.
22. SCHULTZE, J. & JOHNSON, P. (1999). A stimulating new target for cancer immunotherapy. Lancet, 354, 1225-1227.
23. STAMENKOVIC, I., CLARK, E.A. & SEED, B. (1989). A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J., 8, 1403-1410.
24. SZOCINSKI, J.L., KHALED, A.R., HIXON, J., HALVERSON, D., FUNAKOSHI, S., FANSLOW, W.C., BOYD, A., TAUB, D.D., DURUM, S.K., SIEGALL, C.B., LONGO, D.L. & MURPHY, W.J. (2002). Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood, 100, 217-223.
25. TAI, Y.T., LI, X.F., CATLEY, L., COFFEY, R., BREITKREUTZ, I., BAE, J., SONG, W., PODAR, K., HIDESHIMA, T., CHAUHAN, D., SCHLOSSMAN, R., RICHARDSON, P., TREON, S.P., GREWAL, I.S., MUNSHI, N.C. & ANDERSON, K.C. (2004). Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res., 64, 2846-2852.
26. TONG, A.W. & STONE, M.J. (2003). Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther., 10, 1-13.
27. VAN KOOTEN, C. & BANCHEREAU, J. (2000). CD40-CD40 ligand. J. Leukocyte Biol., 67, 2-17.
28. VESTAL, R.E., WINGETT, D.G. & KNIGHT, L.K. (1997). Expression of CD40 in breast, colon, lung, and ovarian tumors (1997). Proc. Am. Assoc. Cancer Res., 38, 230 (abstr 1550).
29. VONDERHEIDE, R.H., DUTCHER, J.P., ANDERSON, J.E., ECKHARDT, S.G., STEPHANS, K.F., RAZVILLAS, B., GARL, S., BUTINE, M.D., PERRY, V.P., ARMITAGE, R.J., GHALIE, R., CARON, D.A. & GRIBBEN, J.G. (2001). Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol., 19, 3280-3287.
30. WANG, D., FREEMAN, G.J., LEVINE, H., RITZ, J. & ROBERTSON, M.J. (1997). Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br. J. Haematol., 97, 409-417.
31. WINGETT, D.G., VESTAL, R.E., FORCIER, K., HADJOKAS, N. & NIELSON, C.P. (1998). CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res. Treat., 50, 27-36.
32. YOUNG, L.S., ELIOPOULOS, A.G., GALLAGHER, N.J. & DAWSON, C.W. (1998). CD40 and epithelial cells: across the great divide (1998). Immunol. Today, 19, 502-506.